Literature DB >> 10537276

MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins.

C H Yam1, W Y Siu, T Arooz, C H Chiu, A Lau, X Q Wang, R Y Poon.   

Abstract

Transforming growth factor-beta (TGF-beta) inhibits cell proliferation in many cell types, and acquisition of TGF-beta resistance has been linked to tumorigenesis. One class of proteins that plays a key role in the TGF-beta signal transduction pathway is the SMAD protein family. MDM2, a key negative regulator of p53, has recently been shown to suppress TGF-beta-induced growth arrest in a p53-independent manner. Here we show that MDM2 and the structurally related protein MDMX can inhibit the transcriptional activity of ectopically expressed SMAD1, SMAD2, SMAD3, and SMAD4. Immunofluorescence staining indicated that ectopically expressed SMAD4 was present in both the cytoplasm and nucleus, and MDM2 and NIDMX were localized mainly to the nucleus and cytoplasm, respectively. When SMAD4 was coexpressed with either MDM2 or MDMX, nuclear accumulation of SMAD4 was strikingly inhibited. We have no evidence that SMAD4 binds directly to MDM2 or MDMX; hence, the inactivation and nuclear exclusion of SMAD4 by MDM2/MDMX may involve other indirect mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537276

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.

Authors:  Changgong Li; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

3.  Mdm2 promotes myogenesis through the ubiquitination and degradation of CCAAT/enhancer-binding protein β.

Authors:  Dechen Fu; Neena Lala-Tabbert; Hwabin Lee; Nadine Wiper-Bergeron
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

4.  Mdm2 and MdmX as Regulators of Gene Expression.

Authors:  Lynn Biderman; James L Manley; Carol Prives
Journal:  Genes Cancer       Date:  2012-03

5.  Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops.

Authors:  Tzu-Hao Cheng; Stanley N Cohen
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

6.  Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.

Authors:  Abhik Datta; Marcia Bellon; Uma Sinha-Datta; Ali Bazarbachi; Yves Lepelletier; Danielle Canioni; Thomas A Waldmann; Olivier Hermine; Christophe Nicot
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

Review 7.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

8.  TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Authors:  Shinako Araki; Jacob A Eitel; Christopher N Batuello; Khadijeh Bijangi-Vishehsaraei; Xian-Jin Xie; David Danielpour; Karen E Pollok; David A Boothman; Lindsey D Mayo
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

9.  Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.

Authors:  Domenico Migliorini; Eros Lazzerini Denchi; Davide Danovi; Aart Jochemsen; Manuela Capillo; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.